# Prognostic factors of neuroblastoma in limited-resource settings

**Authors:** Roberta Gomes Ribeiro Gonçalves Pinto, Mecneide Mendes Lins, Kaline Maria Maciel de Oliveira Pereira, Ticiana Ester Mattos Pascoal Meira, Eduarda Coutinho Albuquerque Neiva Coêlho, Alice Rodrigues Barbosa de Moraes, Marina Lundgren de Melo Batista, Leticia Ribeiro Maciel Pereira, Maria Júlia Gonçalves de Mello

PMC · DOI: 10.1590/1984-0462/2025/43/2024200 · Revista Paulista de Pediatria · 2025-07-28

## TL;DR

This study identifies elevated LDH levels and stage 4 as risk factors for death in children with neuroblastoma in low-income countries.

## Contribution

The study provides a viable risk classification for neuroblastoma in limited-resource settings using LDH levels and staging.

## Key findings

- LDH ≥640.5 U/L was a significant risk factor for death (HRa 2.49; p<0.001).
- Stage 4 neuroblastoma was associated with increased mortality (HRa 1.67; p=0.047).
- Overall survival was 32.4%, with distinct survival curves based on LDH and staging.

## Abstract

This study aimed to analyze survival and risk factors for death in children with neuroblastoma that may contribute to a viable risk classification for low-income countries.

A historic cohort involving patients under 19 years of age with neuroblastoma was followed at a reference center in Northeast Brazil between July 2005 and July 2020. Data on sociodemographic, were collected. The outcomes studied were recurrence, disease progression, and five-year mortality. Multivariate analysis of Cox proportional hazards for death was performed. Overall and eventfree survivals were evaluated using the Kaplan-Meier method and the comparison between the groups studied, by the log-rank test.

Patients (n=126) were predominantly female with a median age of 26.5 months. Most presented primary adrenal, tumor stage 4 according to the International Neuroblastoma Staging System, unfavorable histology, and median serum lactate dehydrogenase (LDH) levels of 640.5 U/L. LDH≥640.5 U/L (hazard ratio [HRa] 2.49; 95% confidence interval [CI] 1.57–3.95; p<0.001) and stage 4 (HRa 1.67; 95%CI 1.00–2.78; p=0.047) were identified as risk factors for death. The overall survival was 32.4%, showing distinct curves regarding LDH serum levels and staging (log-rank p<0.05); the event-free survival was 26.3%.

Elevated LDH serum levels were a risk factor for five-year mortality, and can be utilized as a prognostic marker in resource-limited settings.

## Linked entities

- **Diseases:** neuroblastoma (MONDO:0005072)

## Full-text entities

- **Genes:** MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}
- **Diseases:** nodular ganglioneuroblastoma (MESH:D018305), cancer (MESH:D009369), infection (MESH:D007239), ganglioneuroma (MESH:D005729), toxicity (MESH:D064420), Kinsbourne syndrome (MESH:D053578), fever (MESH:D005334), INSS (MESH:D009447), Pepper syndrome (MESH:C536438), mediastinal mass (MESH:D008477), metastases (MESH:D009362), bone marrow metastasis (MESH:D001855), bone pain (MESH:D010146), Death (MESH:D003643), abdominal pain (MESH:D015746), Respiratory failure (MESH:D012131)
- **Chemicals:** NB-91 (-), vincristine (MESH:D014750), topotecan (MESH:D019772), carboplatin (MESH:D016190), cyclophosphamide (MESH:D003520), mesna (MESH:D015080), paraffin (MESH:D010232), catecholamines (MESH:D002395), doxorubicin (MESH:D004317), ifosfamide (MESH:D007069), etoposide (MESH:D005047)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12313317/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12313317/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12313317/full.md

---
Source: https://tomesphere.com/paper/PMC12313317